Afelimomab
In this article, we will explore the topic of Afelimomab in detail, analyzing its origins, evolution and relevance in today's society. Introducing readers to the history and context of Afelimomab, we will delve into its many facets and dimensions, from its cultural impacts to its implications in daily life. Through a comprehensive approach, we will examine the different perspectives and opinions on Afelimomab, providing a panoramic view that will allow us to understand its importance in the contemporary panorama. By the end of this reading, we hope that readers will have gained a more complete and enriched understanding of Afelimomab, while also feeling motivated to reflect on its own meaning and relevance in their lives.
| Monoclonal antibody | |
|---|---|
| Type | F(ab')2 fragment |
| Source | Mouse |
| Target | TNFα |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]
References
- ^ Rondon E, Venkataraman R (August 2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
- ^ Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. (November 2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–82. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628. S2CID 23321488.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |